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APPENDIX
For supplemental references, a ﬁgure, and a table, please see the online
version of this article.Letters to the EditorApplication of the
Gompertz Method for
Evaluating Survival Gains
in Patients Receiving Cardiac
Resynchronization TherapyIn the paper by Finegold et al. (1), the methods used for the
survival analysis have been described with insufﬁcient detail. It
appears, however, that lifespan gains were calculated through
a separate analysis of each individual trial, were then “weighted
according to study size,” and ﬁnally were “averaged across all trials.”
This step of the survival analysis, which is described by Finegold
et al. (1) in their Results section and not in the Methods, needs to
be clariﬁed in at least 2 aspects. First, the weighting process is
essential to any meta-analysis, because in this way, between-trial
variations are explored and conﬁdence intervals for differences are
estimated. So, one question is why the results were presented
exclusively on the basis of the pooled (or “average”) survival gain,
without any information on the gains calculated for each individual
trial and without any measure of statistical variability. Second, in
the calculation of the trial-speciﬁc lifespan gains, the authors state
that they “used the Gompertz method for this.” However, ﬁtting a
Kaplan-Meier curve to the Gompertz equation is a complex task
from a mathematical and statistical viewpoint (2,3), and it is un-
fortunate that no details were provided on this point.
If these inconsistencies are clariﬁed, this paper can be viewed
as an important contribution in this ﬁeld, mainly for reasons
of cost-effectiveness. Given that the gain of 1 month can be
valued at approximately V5,000 according to common bench-
marks (4–7), this study shows that the clinical beneﬁt of
this procedure is not, as suggested by short-term data, onlyapproximately 1 month (equivalent to V5,000, which would not
even cover the device cost) but could be as high as 6.5 months
(equivalent to more than V30,000, which is much more than the
cost of the device).*Andrea Messori, PharmD
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Gompertz Method for
Evaluating Survival Gains
in Patients Receiving Cardiac
Resynchronization TherapyWe thank Dr. Messori and colleagues for asking for clariﬁcation on
the Methods used in our recent paper.
We should clarify that our Figure 2 used an average weighted
solely by the sample size of the 5 trials, because this seemed
appropriate weighting for combining rates across trials. The reason
